In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...
Suleika Jaouad's leukemia experience highlights the importance of mindfulness and support networks in managing the disease.
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...
Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax improved outcomes for untreated chronic lymphocytic leukemia ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
The Voice features host Gloria Burns in a meaningful conversation with Roxie Soto from the Leukemia & Lymphoma Society (LLS) to highlight the organization’s mission, patient support programs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback